Targeting Treg cells in cancer immunotherapy

Abstract Foxp3‐expressing regulatory T (Treg) cells, which are indispensable for preventing autoimmunity, also suppress effective tumor immunity. Treg cells abundantly infiltrate into tumor tissues, which is often associated with poor prognosis in cancer patients. Removal of Treg cells enhances anti‐tumor immune responses but may also elicit autoimmunity. A key issue in devising Treg‐targeting cancer immunotherapy is, therefore, how to specifically deplete Treg cells infiltrating into tumor tissues without affecting tumor‐reactive effector T cells, while suppressing autoimmunity. This can be achieved by differentially controlling Treg and effector T cells by various ways. In this review, we discuss how…

• JA
  Japan Agency for Medical Research and Development

  Award: 18cm0106303h0003
• MO
  Ministry of Education, Culture, Sports, Science and Technology

  Award: 16H06295
• JS
  Japan Society for the Promotion of Science

  Awards: 17K15723, 26253030, 26860331
• JS
  Japan Science and Technology Agency

  Award: 18gm0010005h0001
• CR
  Core Research for Evolutional Science and Technology

  Award: 17gm0410016h0006